openPR Logo
Press release

Janus Kinase (JAK) Inhibitors Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years | Janssen Inc., Galapagos, Gilead Sciences, Pfizer, Eli Lilly and Company, Incyte, AbbVie, Concert Pharmaceuticals, Inc., Portola Pha

04-23-2019 10:39 AM CET | Health & Medicine

Press release from: Janus Kinase (JAK) Inhibitors - Pharma Proff

Janus Kinase (JAK) Inhibitors Pipeline to Witness Significant

JAK comprises four receptors JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2) which help in cytokine mediated signaling through the JAK/STAT pathway. There are two nearly identical phosphate transferring domains present in JAKs. The first domain demonstrates kinase activity while the other regulates the activity of the first via negative inhibition. The mutations in the JAK/STAT pathway leads to different medical conditions.

Download the sample report: https://www.pharmaproff.com/request-sample/1216

The JAK inhibitors work by blocking the cytokine mediated signaling via JAK/STAT pathway which plays an important role in immune regulation and growth.

The pipeline of JAK inhibitors is quite robust with drugs being developed in the Pre-Registration, Phase III, Phase II, Phase I, Pre-Clinical, and Discovery stage of development. Also, majority of the pipeline products are currently undergoing Phase II clinical studies.

Get the detailed analysis: https://www.pharmaproff.com/pressrelease/janus-kinase-inhibitors-pipeline

According to the research findings, majority of the JAK inhibitors in the pipeline are being developed for oral administration. It has been observed that the oral route of medication is convenient, available in delayed or rapid release formulation, less risk of systemic infections, and inexpensive in nature, and also provides improved patient’s compliance. Moreover, the drugs administered by this route are less invasive and can be modified for extended release, thereby increasing the bioavailability. Also, administration of JAK inhibitors through oral route have shown promising results in the clinical studies.

Make enquiry before purchase: https://www.pharmaproff.com/enquiry/1216

The companies developing JAK inhibitors have shown positive clinical results in the various phases of drug development. For instance, in January 2018, LEO Pharma A/S’s collaborator Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. announced the topline results from delgocitinib’s Phase III comparative study. The primary endpoints of the study were met and there were no clinically significant findings on safety and tolerability of delgocitinib within the treatment period. Similarly, Astellas Pharma Inc. in February 2018, announced results of two-Phase II trials on peficitinib wherein the drug demonstrated superiority over the placebo w.r.t the primary endpoints. Also, the safety profile of Peficitinib was found to be consistent.

In the wake of various strategic development activities, Theravance Biopharma Inc. and Janssen Global LLC signed an agreement in February 2018 to jointly develop and commercialize Phase I product, TD-1473. Similarly, Galapagos NV and Gilead Sciences Inc. in December 2015 signed a partnership agreement to develop and commercialize filgotinib for the treatment of rheumatoid arthritis and Crohn’s disease. Therefore, collaborating and partnering with other companies can help the current players in the pipeline to expand their drug portfolio for the treatment of diseases related to the JAK/STAT pathway.

Pfizer Inc., Eli Lilly and Company, Incyte Corporation, AbbVie Inc., Concert Pharmaceuticals Inc., Portola Pharmaceuticals Inc., Italfarmaco S.p.A, CTI BioPharma Corp., Theravance Biopharma Inc., Janssen Global LLC, and Galapagos NV are some of the companies involved in the development of JAK inhibitors.

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Janus Kinase (JAK) Inhibitors Pipeline to Witness Significant Growth due to Positive Clinical Results in the Coming Years | Janssen Inc., Galapagos, Gilead Sciences, Pfizer, Eli Lilly and Company, Incyte, AbbVie, Concert Pharmaceuticals, Inc., Portola Pha here

News-ID: 1713826 • Views:

More Releases for JAK

Janus Kinase (JAK) Inhibitors Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Janus Kinase (JAK) Inhibitors Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Janus Kinase (JAK) Inhibitors players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyze the Janus Kinase (JAK)
Global Janus Kinase (JAK) Inhibitors Market to Witness a Pronounce Growth During …
LP INFORMATION offers a latest published report on Janus Kinase (JAK) Inhibitors Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. According to this study, over the next five years the Janus Kinase (JAK) Inhibitors market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million
Tyrosine Kinase JAK Inhibitors Market Pegged for Robust Expansion by 2026
Tyrosine kinases are enzymes capable of transferring the phosphate group from ATP (adenosine triphosphate) to a cellular protein. They function as an on or off switch for several cellular mechanisms. On the protein, the phosphate group is affiliated to the tyrosine amino acid. Tyrosine kinases are a subclass of the larger group of protein kinases that connect phosphate groups to extra amino acids (threonine and serine). In interconnecting signals in
JAK-Metalli named Swedish Steel Prize 2018 finalist
/ins For developing a new cutting solution for vegetation management that is safer, less energy intensive and more durable, JAK-Metalli has been nominated for the Swedish Steel Prize 2018. The Swedish Steel Prize is awarded annually to recognize the most innovative design utilizing high-performance steel. JAK-Metalli Oy, from Finland, is one of the four finalists for this year’s prize, which will be awarded during a ceremony in Stockholm, Sweden on May
Tyrosine Kinase JAK Inhibitors Market Sees Promising Growth to 2022
HTF MI presents an in-depth assessment of current Tyrosine Kinase JAK Inhibitors key market drivers, market size and trends and Asia-Pacific Tyrosine Kinase JAK Inhibitors opportunities, challenges, and restraints as well as key market segments, technological updates, impact of any regulatory policies as well as key market segments. The research study provides forecasts for Tyrosine Kinase JAK Inhibitors investments till 2022. If you are involved in the Tyrosine Kinase JAK
Global Tyrosine Kinase JAK Inhibitors Market Challenges & Industry Analysis by 2 …
Qyresearchreports include new market research report "Global Tyrosine Kinase JAK Inhibitors Market Research Report 2018" to its huge collection of research reports. Tyrosine Kinase JAK Inhibitors Market Research Report is a comprehensive market study, which has been created with a sole goal to armor existing and new players to gain advantage over their competitors. For the development of the report, proven research methodology and reliable analytical tools are applied to gain